Not Signed In - Vioxx Reduces The Risk Of Colorectal Polyps, Study Finds
Fri, 01 Sep 2006 08:00 PM EST
... A researcher from Dartmouth reports the results of a clinical trial that shows that the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (VIOXX®) reduces the risk of colorectal adenomas, or polyps. Polyps are benign tumors that are precursors to colon cancer, and they are often found in older adults. [click link for full article] ...
Related Topics
- Polyps
- Colorectal Cancer
- Colon Polyps
- Rofecoxib
- Risk Factors
- Security Risk Assessment
- Cardiac Risk
- High Risk Pregnancy
- Colonoscopy
- Youth Risk Behaviors
- Cardiovascular Diseases And Disorders
- Cancer, Colorectal
- CHF
- Rofecoxib Oral Suspension
- Colorectal Cancer, Childhood
- Heart Disease
- Nasal polyps
- Valdecoxib
- Atherosclerosis
- Radiation Studies
email this page
print this page
bookmark this page
feedback on this page
